Elanco Animal Health (NYSE:ELAN) Insider Shiv O’neill Buys 3,998 Shares

Elanco Animal Health Incorporated (NYSE:ELAN) insider Shiv O’neill acquired 3,998 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the acquisition, the insider directly owned 87,832 shares of the company’s stock, valued at $2,071,078.56. The trade was a 4.77% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Elanco Animal Health Stock Up 0.1%

Elanco Animal Health stock opened at $23.63 on Wednesday. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98. The firm’s fifty day simple moving average is $24.54 and its 200-day simple moving average is $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $11.80 billion, a P/E ratio of -57.63, a P/E/G ratio of 1.42 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the company posted $0.26 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ELAN. KeyCorp raised their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Citigroup lifted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, TD Cowen raised their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Institutional Trading of Elanco Animal Health

Hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio increased its position in shares of Elanco Animal Health by 113.0% during the second quarter. Public Employees Retirement System of Ohio now owns 330,645 shares of the company’s stock valued at $8,137,000 after purchasing an additional 175,412 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Elanco Animal Health in the 2nd quarter valued at $260,000. Corient Private Wealth LP bought a new position in shares of Elanco Animal Health during the 2nd quarter worth about $8,565,000. Park West Asset Management LLC bought a new position in shares of Elanco Animal Health during the 2nd quarter worth about $24,979,000. Finally, Bank of America Corp DE boosted its position in shares of Elanco Animal Health by 16.4% during the 2nd quarter. Bank of America Corp DE now owns 3,909,871 shares of the company’s stock valued at $96,222,000 after acquiring an additional 551,656 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.